Popular weight-loss drugs shouldn’t carry suicide warnings, FDA says
U.S. Food and Drug Administration officials say a comprehensive review “found no increased risk” related to suicide among users of the GLP-1 drugs, including Eli Lilly and Co.’s Zepbound, used to treat obesity.